BiotechTube

Olomorasib

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hepatic Insufficiency

Conditions

Hepatic Insufficiency, Healthy

Trial Timeline

Dec 6, 2024 → Aug 25, 2025

NCT ID
NCT06719128

About Olomorasib

Olomorasib is a phase 1 stage product being developed by Eli Lilly for Hepatic Insufficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT06719128. Target conditions include Hepatic Insufficiency, Healthy.

What happened to similar drugs?

3 of 18 similar drugs in Hepatic Insufficiency were approved

Approved (3) Terminated (5) Active (12)
✅RifaximinBausch HealthApproved
✅Placebo + RifaximinBausch HealthApproved
✅Rifaximin + LactuloseBausch HealthApproved
🔄cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
🔄PhosphatidylcholineSanofiPhase 3
❌oxaliplatin (SR96669) + capecitabine + sorafenibSanofiPhase 3
🔄Givosiran + PlaceboAlnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT07124013Phase 1Completed
NCT07044271Phase 1Recruiting
NCT06719128Phase 1Completed

Competing Products

20 competing products in Hepatic Insufficiency

See all competitors
ProductCompanyStageHype Score
ITF2357BiotrialPhase 1
19
GB1211 + PlaceboComac MedicalPhase 1/2
18
ACT-541468 25 mg + ACT-541468 25 mg (or 10 mg depending on interim results)IdorsiaPhase 1
23
SimufilamCassava SciencesPhase 1
19
cisplatin + gemcitabine hydrochlorideEli LillyPhase 3
40
exatecan mesylateDaiichi SankyoPhase 2
35
DS-3201bDaiichi SankyoPhase 1
29
QuizartinibDaiichi SankyoPhase 1
29
QuizartinibDaiichi SankyoPhase 1
36
PexidartinibDaiichi SankyoPhase 1
29
Tivantinib + Tivantinib + Tivantinib + TivantinibDaiichi SankyoPhase 1
29
BocidelparAstellas PharmaPhase 1
29
fezolinetantAstellas PharmaPhase 1
29
enzalutamideAstellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP2215Astellas PharmaPhase 1
29
BPN14770ShionogiPhase 1
29
S-217622ShionogiPhase 1
29
LemborexantEisaiPhase 1
29
LenvatinibEisaiPhase 1
29